|
Condensed Consolidated Statements of Operations (Unaudited) (USD $)
|
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
|
Sep. 30, 2012
|
Sep. 30, 2011
|
Sep. 30, 2012
|
Sep. 30, 2011
|
|
| Income Statement [Abstract] | ||||
| Product and service revenue | $ 4,273,385 | $ 4,312,885 | $ 18,711,555 | $ 11,927,135 |
| Research and development contract revenue | 502,269 | 994,244 | 1,475,338 | 3,342,187 |
| Licensed technology revenue | 163,125 | 489,375 | ||
| Total revenue | 4,775,654 | 5,470,254 | 20,186,893 | 15,758,697 |
| Cost of product and service revenue | 10,848,860 | 7,565,994 | 28,552,076 | 19,187,617 |
| Cost of research and development contract revenue | 791,322 | 1,695,171 | 2,389,844 | 5,505,767 |
| Research and development expense | 1,284,975 | 1,478,847 | 4,089,509 | 3,647,821 |
| Selling, general and administrative expenses | 3,053,434 | 3,606,505 | 10,556,495 | 11,051,020 |
| Gain on sale of leased assets | (673,358) | (673,358) | ||
| Amortization of intangible assets | 578,090 | 584,606 | 1,726,854 | 1,754,568 |
| Operating loss | (11,781,027) | (8,787,511) | (27,127,885) | (24,714,738) |
| Interest and other income and net realized losses from available-for-sale securities | 80,046 | 99,740 | 171,260 | 220,862 |
| Change in fair value of common stock warrant liability | 1,434,866 | 2,414,267 | 3,726,667 | 4,204,787 |
| Interest and other expense and foreign currency gain (loss) | (59,349) | (17,042) | (158,162) | 2,675 |
| Net loss | $ (10,325,464) | $ (6,290,546) | $ (23,388,120) | $ (20,286,414) |
| Loss per share: | ||||
| Basic and diluted (in dollars per share) | $ (0.27) | $ (0.28) | $ (0.71) | $ (1.16) |
| Weighted average number of common shares outstanding (in shares) | 37,977,052 | 22,676,114 | 33,107,175 | 17,441,767 |